BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 29869612)

  • 21. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements.
    Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ
    Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis.
    Deel MD; Slemmons KK; Hinson AR; Genadry KC; Burgess BA; Crose LES; Kuprasertkul N; Oristian KM; Bentley RC; Linardic CM
    Clin Cancer Res; 2018 Jun; 24(11):2616-2630. PubMed ID: 29514840
    [No Abstract]   [Full Text] [Related]  

  • 23. PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
    Searcy MB; Larsen RK; Stevens BT; Zhang Y; Jin H; Drummond CJ; Langdon CG; Gadek KE; Vuong K; Reed KB; Garcia MR; Xu B; Kimbrough DW; Adkins GE; Djekidel N; Porter SN; Schreiner PA; Pruett-Miller SM; Abraham BJ; Rehg JE; Hatley ME
    Nat Commun; 2023 Nov; 14(1):7291. PubMed ID: 37968277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma.
    Xie Z; Babiceanu M; Kumar S; Jia Y; Qin F; Barr FG; Li H
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13126-13131. PubMed ID: 27799565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway.
    Schmitt-Ney M; Camussi G
    PLoS One; 2015; 10(3):e0121474. PubMed ID: 25806826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma.
    Kanayama T; Miyachi M; Sugimoto Y; Yagyu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Sci Rep; 2021 Sep; 11(1):18802. PubMed ID: 34552155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
    Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
    Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma.
    Bharathy N; Suriyamurthy S; Rao VK; Ow JR; Lim HJ; Chakraborty P; Vasudevan M; Dhamne CA; Chang KT; Min VL; Kundu TK; Taneja R
    J Pathol; 2016 Nov; 240(3):269-281. PubMed ID: 27453350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
    Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
    Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
    Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
    Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IRIZIO: a novel gene cooperating with PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS).
    Picchione F; Pritchard C; Lagutina I; Janke L; Grosveld GC
    Carcinogenesis; 2011 Apr; 32(4):452-61. PubMed ID: 21177767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process.
    Yuan H; Qin F; Movassagh M; Park H; Golden W; Xie Z; Zhang P; Sklar J; Li H
    Cancer Discov; 2013 Dec; 3(12):1394-403. PubMed ID: 24089019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
    Linardic CM; Naini S; Herndon JE; Kesserwan C; Qualman SJ; Counter CM
    Cancer Res; 2007 Jul; 67(14):6691-9. PubMed ID: 17638879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease.
    Lagutina IV; Valentine V; Picchione F; Harwood F; Valentine MB; Villarejo-Balcells B; Carvajal JJ; Grosveld GC
    PLoS Genet; 2015; 11(2):e1004951. PubMed ID: 25659124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sphingosine Induces Apoptosis and Down-regulation of
    Ahn EH; Lee MB; Seo DJ; Lee J; Kim Y; Gupta K
    Anticancer Res; 2018 Jan; 38(1):71-76. PubMed ID: 29277758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma.
    Wang W; Kumar P; Wang W; Epstein J; Helman L; Moore JV; Kumar S
    Cancer Res; 1998 Oct; 58(19):4426-33. PubMed ID: 9766674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy.
    Rengaswamy V; Zimmer D; Süss R; Rössler J
    J Control Release; 2016 Aug; 235():319-327. PubMed ID: 27261335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells.
    Yoshida H; Miyachi M; Sakamoto K; Ouchi K; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Imamura T; Iehara T; Kakazu N; Hojo H; Hosoi H
    Oncogene; 2014 Dec; 33(49):5601-8. PubMed ID: 24213582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.